A five-gene signature and clinical outcome in non-small-cell lung cancer.

By Hsuan-Yu Chen, Sung‐Liang Yu, Chun-Houh Chen, G. Chang, Chih-Yi Chen, A. Yuan, Chiou-Ling Cheng, Chien-Hsun Wang, H. Terng, S. Kao and 7 more. New England Journal of Medicine, 2007

900 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/bf13ec0f484e87fe24f64dc294d5c900cbc6ee53

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Zhibin Hu
R. Aguirre-Gamboa
X. Chen
J. Hou
Yang Zhao
Hugo Gómez-Rueda
T. Tian
Emmanuel Martínez-Ledesma

Citations in the corpus

MicroRNA signature predicts survival and relapse in lung cancer. (2008, background): “In fact, the results of predictor power generated from microRNA or mRNA signatures had been reported in the literature (Beer et al., 2002; Bloomston et al., 2007; Calin et al., 2005; Chen et al., 2007; Endoh et al., 2004; Lossos et al., 2004; Potti et al., 2006; Yanaihara et al., 2006).”
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. (2010, methodology): “We assigned each patient a risk score according to a linear combination of the expression level of the miRNA, weighted by the regression coefficient from the training samples.(2,11,17) The risk score was calculated as follows: risk-score (0.”
MediBoost: a Patient Stratification Tool for Interpretable Decision Making in the Era of Precision Medicine (2016, background): “The requirements of stratification and interpretability are the reason why decision trees produced by machine learning algorithms such as C4.5, ID3, and CART, are so widely used in medicine 9–16 .”
SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis (2013, background): “The second NSCLC biomarker was proposed by Chen et al. [18] and contains the genes DUSP6 , MMD , STAT1 , ERBB3 , and LCK .”
Gene Expression-Based Classification of Non-Small Cell Lung Carcinomas and Survival Prediction (2010, methodology): “The survival related signatures were 20- and 6-probe set predictors developed by Lee et al [20], one signature derived from Affymetrix U133A chips [21], one from Affymetrix HuGeneFL chips [22,23], two from other types of oligonucleotide array [24,25], and one from RTPCR assays [26] (Table S10).”